Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Chemotherapy & Immunotherapy
Androgen deprivation therapy
What androgen deprivation therapy (ADT) is, how lowering testosterone slows prostate cancer growth, LHRH agonists, antagonists and anti-androgens, approximate costs in Turkey compared with the UK, US and Germany, management of side effects, monitoring PSA levels, expected treatment duration and how multidisciplinary oncology teams plan care.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Chemotherapy & Immunotherapy
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Androgen Deprivation Therapy
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Androgen deprivation therapy in Turkey: what it is and how hormone suppression works
Androgen deprivation therapy (ADT) is a systemic medical treatment for prostate cancer that lowers circulating male hormones, primarily testosterone and dihydrotestosterone (DHT). Because prostate cancer cells rely on androgens to grow and divide, reducing these hormones slows tumor progression and triggers cancer cell death. Hospital oncology departments in Turkey offer androgen deprivation therapy in Turkey using modern depot injections, oral receptor blockers, and detailed diagnostic staging.
Hormone therapy is not a standalone cure for widespread disease, but it forms an essential foundation for intermediate-risk, high-risk, locally advanced, and metastatic prostate cancer. Depending on the cancer stage, it is given for six months to three years alongside radiotherapy, or continued indefinitely for advanced cases. For an overview of comprehensive cancer care, explore our guide to oncology treatments in Turkey.
How does androgen deprivation therapy work against prostate cancer?
To understand what is androgen deprivation therapy and its mechanism, consider the hormonal signalling pathway. The brain releases luteinising hormone-releasing hormone (LHRH), prompting the pituitary gland to release luteinising hormone (LH), which signals the testes to produce ninety-five percent of the body's testosterone.
Medical therapy disrupts this pathway in two ways. LHRH agonists (such as leuprorelin or goserelin) initially stimulate pituitary receptors, causing a temporary hormone surge before exhausting receptors and reducing testosterone to castrate levels (below 50 ng/dL) within three to four weeks. Short-term anti-androgen tablets are prescribed to prevent this flare. GnRH antagonists (such as degarelix or oral relugolix) block receptors directly, achieving castrate levels within days without a surge. Without testosterone, androgen receptors on cancer cells remain inactive, arresting tumor growth.
Does androgen deprivation therapy actually work? Clinical evidence and limitations
Clinical trials coordinated by organisations such as the European Association of Urology (EAU) and ESMO confirm that does androgen deprivation therapy work reliably to control prostate cancer. When combined with radiotherapy for high-risk localised disease, eighteen to thirty-six months of hormone deprivation significantly improves overall survival. In metastatic hormone-sensitive cases, trials show improved progression-free survival when hormone suppression is combined with docetaxel chemotherapy or novel anti-androgens.
However, hormone therapy has limits. While it reliably reduces prostate-specific antigen (PSA) levels and shrinks tumors, it does not permanently eliminate metastatic cancer. Over time, malignant cells adapt to low testosterone, progressing to castration-resistant prostate cancer (CRPC). In advanced resistance, patients may benefit from targeted therapy for genetic mutations or select immunotherapy options, while maintaining basic hormone suppression.
Androgen deprivation therapy cost in Turkey compared with the UK, US and Germany
The androgen deprivation therapy cost depends on the prescribed drug, depot formulation length (one, three, or six months), imaging requirements, and specialist consultations. The table below lists approximate ranges for diagnostic staging and a three-to-six-month depot regimen.
| Country | Approximate cost range |
|---|---|
| Turkey | €800 – €3,500 |
| United Kingdom | €2,500 – €7,000 |
| United States | €4,000 – €14,000 |
| Germany | €2,200 – €6,500 |
Factors affecting the androgen deprivation therapy price include whether treatment uses standard LHRH agonists, newer antagonists, or oral second-generation agents. Packages in Turkey often bundle staging scans (such as PSMA PET-CT), blood tests, oncologist consultations, and initial injections into a single written quote.
Medical castration, surgical orchiectomy or novel anti-androgens?
Patients evaluating androgen deprivation therapy Turkey have several ways to achieve testosterone suppression. Uro-oncologists assess disease stage, cardiovascular health, and preferences when recommending an approach.
| Method | Best suited to | Typical limits |
|---|---|---|
| LHRH agonists and antagonists | Locally advanced, high-risk or metastatic cancer where reversible suppression is preferred | Requires ongoing depot injections; agonists need short-term anti-androgen cover against testosterone flares |
| Bilateral orchiectomy (surgical) | Patients wanting rapid, permanent androgen suppression without regular injections or clinic visits | Irreversible surgical removal of testicular tissue; psychological impact; standard minor surgical risks |
| Novel hormonal agents (second-generation) | Metastatic hormone-sensitive or castration-resistant prostate cancer requiring intensified blockade | Substantially higher medication costs; requires regular liver function, blood pressure and cardiac monitoring |
Bilateral orchiectomy is an outpatient surgical procedure that permanently lowers testosterone without recurring injection costs. Most international patients opt for medical depot injections, which provide flexibility for intermittent dosing if PSA levels remain undetectable.
Who is an appropriate candidate for hormone therapy, and who is not?
Androgen deprivation therapy suits specific stages of prostate cancer where lowering testosterone provides clinical benefit. Good candidates include:
- Men with intermediate-risk or high-risk localised prostate cancer receiving radiotherapy.
- Patients with locally advanced disease spreading to regional lymph nodes.
- Men with biochemical recurrence (rapidly rising PSA) following surgery or radiation.
- Patients presenting with metastatic hormone-sensitive prostate cancer.
Conversely, hormone therapy is not recommended as primary monotherapy for low-risk localised prostate cancer, where active surveillance or surgery is standard. It is also unsuitable for patients with severe unmanaged cardiovascular conditions or severe untreated osteoporosis until bone-protecting treatments are established.
The treatment protocol: how hormone therapy is administered step by step
Administering hormone therapy follows a systematic medical protocol to ensure safety and steady suppression:
- Staging and baseline tests: Pathology is verified, and baseline PSA, testosterone, liver function, cardiovascular health, and DEXA bone density are documented. A PSMA PET-CT scan maps any metastases.
- Flare protection: If starting an LHRH agonist, oral anti-androgens (such as bicalutamide) are taken daily for two weeks before and two weeks after the injection to block hormone surge effects.
- Depot injection: The medication is injected subcutaneously into the abdomen or intramuscularly into the gluteus, releasing active drug over one, three, or six months.
- Tolerance review: The oncology team reviews patient tolerance, providing guidance on managing hot flushes and fatigue.
- Monitoring schedule: Serum PSA and testosterone are tested every three months to verify castrate levels and disease stability.
Androgen deprivation therapy recovery, daily life and managing side effects
Because hormone therapy is an injection rather than major surgery, androgen deprivation therapy recovery focuses on adapting to low testosterone levels rather than wound healing. Patients can travel and resume daily activities immediately after receiving their depot injection.
International guidelines from the NHS emphasize that structured exercise is vital during hormone therapy. Regular resistance training and brisk walking preserve muscle mass, counter fatigue, prevent weight gain, and support bone strength. Nutritional support includes calcium and vitamin D supplementation alongside a heart-healthy diet. Traveling patients typically complete their consultations, baseline scans, and initial injection within three to five days in Turkey before returning home.
Realistic expectations: what PSA monitoring and scans show
Expected results from hormone therapy are measured through biochemical markers and imaging rather than visual changes. In responding patients, serum PSA levels drop sharply within the first eight to twelve weeks, frequently falling below 0.1 ng/mL.
Follow-up PSMA PET-CT or MRI scans generally show shrinkage of the prostate tumor and regression of lymph node or bone lesions. However, patients should maintain realistic expectations. A low PSA confirms that hormone-sensitive cells are suppressed, but does not mean all cancer cells have been eliminated. In addition, physical changes such as reduced muscle tone or mild fluid retention are drug side effects, not signs of cancer activity.
Risks, metabolic changes and long-term side effects
Suppressing testosterone causes recognized physiological effects. Before starting, oncologists discuss potential androgen deprivation therapy side effects and management plans:
- Hot flushes: Vasomotor episodes affect most men, causing sudden sweating and warmth.
- Sexual changes: Loss of libido and erectile dysfunction are expected consequences of testosterone suppression.
- Metabolic shifts: Loss of lean muscle mass, increased body fat, insulin resistance, and elevated cholesterol.
- Bone density loss: Prolonged therapy accelerates bone loss, increasing osteopenia and fracture risk; DEXA scans and bone-protective agents are used when required.
- Cardiovascular considerations: Long-term suppression can raise cardiovascular strain, making blood pressure monitoring essential.
- Mood and fatigue: Mild mood changes, sleep disturbance, and persistent fatigue can occur.
Professional guidelines from ESMO and the NHS recommend routine bone and cardiovascular monitoring during long-term hormone therapy.
How to choose an oncology hospital in Turkey and red flags to avoid
Cancer treatment requires accredited hospital care. Look for comprehensive cancer centers accredited by Joint Commission International (JCI) or licensed by the Turkish Ministry of Health. Verify that a multidisciplinary tumor board—including medical oncologists, urologists, and radiation specialists—reviews your case collaboratively.
Red flags include clinics offering hormone injections without tissue biopsy or staging scans, guarantees of permanent cures, quotes with hidden drug fees, and lack of written documentation for your home doctor. Essential questions to ask the clinic include:
- Does a multidisciplinary tumor board review my pathology and imaging before prescribing?
- Which specific medication and depot duration do you recommend, and why?
- Will I receive a detailed English medical report and prescription for my home doctor?
- What baseline tests (PSA, testosterone, DEXA scan, cardiac review) are included?
- What plan is in place to manage bone loss and metabolic side effects?
Learn more about treatment logistics on our how it works page. To submit your medical reports for a personalized plan, request a free quote.
Hospitals with Oncology in Turkey
Frequently asked questions
Androgen deprivation therapy, or hormone therapy, is a medical treatment for prostate cancer that lowers male sex hormones, mainly testosterone, to castrate levels. Depriving prostate cancer cells of testosterone slows their growth, shrinks tumors, and causes cancer cell death across localized, locally advanced, and metastatic disease stages.
Yes, it reliably lowers PSA levels and controls prostate tumor progression. Extensive clinical trials demonstrate that adding hormone deprivation to radiotherapy significantly improves overall survival in high-risk localized cancer, while in metastatic disease it serves as the foundational treatment, often combined with chemotherapy or novel anti-androgens.
Approximate costs in Turkey range from €800 to €3,500, compared with €2,500 to €7,000 in the UK and €4,000 to €14,000 in the US. The price depends on the chosen medication, depot duration, pre-treatment imaging like PSMA PET-CT, and whether multi-specialist consultations are bundled.
Rather than visible physical transformations, results appear on blood tests and scans. Responding patients typically experience a steep fall in PSA levels within eight to twelve weeks, alongside tumor shrinkage on MRI or PSMA PET-CT scans, while physical changes mainly involve temporary muscle loss or weight redistribution.
Because hormone therapy involves injections rather than surgery, physical recovery from the injection is immediate. Long-term adaptation involves managing hormonal changes: fatigue, hot flushes, and muscle loss. Regular resistance exercise, a balanced diet, and calcium supplements help patients maintain normal active routines throughout treatment.
The depot injection feels similar to a routine vaccination, with minor temporary soreness or redness at the injection site in the abdomen or gluteus. It is not an operative procedure, so there is no surgical wound pain unless a patient selects surgical bilateral orchiectomy.
Treatment duration varies by cancer stage. Men with intermediate-risk or high-risk localised cancer receiving radiotherapy typically have hormone suppression for six months to three years. In metastatic prostate cancer, hormone therapy is generally continued long term, either continuously or intermittently based on PSA response.
It is an established, guideline-backed oncology treatment, but profound testosterone reduction carries systemic side effects. These include hot flushes, loss of libido, reduced bone mineral density, fatigue, and metabolic changes. Oncologists monitor cardiovascular health and bone density regularly to manage risks proactively.
Neither is right for everyone. Medical depot injections are reversible and allow intermittent treatment regimes, which many men prefer. Surgical orchiectomy is an irreversible outpatient procedure that permanently stops testicular testosterone production without ongoing injection visits or repeated medication expenses.
Most international patients stay three to five days in Turkey. This window provides adequate time for comprehensive staging scans, blood panels, a multidisciplinary tumor board review, the initial depot injection, and receiving detailed documentation for their home physician.
Patient stories